January 13, 2020 - 1:44pm EST by
2020 2021
Price: 0.75 EPS 0 0
Shares Out. (in M): 20 P/E 0 0
Market Cap (in $M): 15 P/FCF 0 0
Net Debt (in $M): 0 EBIT 0 0
TEV ($): 0 TEV/EBIT 0 0

Sign up for free guest access to view investment idea with a 45 days delay.



NVLNF at $0.75 probably yields >=30% IRR per the background linked below (i.e. each NVLNF share will be exchanged for about .634 shares of AMYT, which trades on LSE, by 4Q2020)

objection to my "probably":
AMYT cannot be hedged, who knows what it is worth
my response to this objection:
On Sept 25, 2019, AMYT announced:
"Amryt has completed the $60 million fundraising by way of the issue of new Ordinary Shares at a price of $1.79 (£1.44 based on an exchange rate of £1:$1.2485) per Ordinary Share to new and existing investors, and certain creditors of Aegerion who backstopped the fundraise."  (source
AMYT also announced that as a result of the above, its largest new shareholders were:



Number of ordinary shares on Admission

Percentage of the issued share capital on Admission

Funds managed by Athyrium Capital Management, LP



Novelion Therapeutics Inc.



Funds managed by Highbridge Capital Management, LLC1



As Athyrium and Highbridge were the largest Aegerion convert holders who backstopped the AMYT fundraise, they increased exposure to the Aegerion drugs in which they've been invested for years. 
At US$1.79 per AMYT share, each share of NVLNF would be worth $1.15 per share. 
The AMYT CEO this month bought ~8k AMYT shares near $1.60 per AMYT share.
I do not hold a position with the issuer such as employment, directorship, or consultancy.
I and/or others I advise hold a material investment in the issuer's securities.


Distribution of AMYT this year, probably in 4Q

    show   sort by    
      Back to top